[424B5] Cineverse Corp. Prospectus Supplement (Debt Securities)

Rhea-AI Filing Summary

Rubrik, Inc. (RBRK) – Form 4 Insider Activity

Chief Financial Officer Kiran Kumar Choudary reported two transactions dated 07/09/2025:

• Option exercise & conversion: 2,000 stock options exercised at a $7.99 strike (Code M) and automatically converted from Class B to Class A shares (Code C) at a reported price of $0.
• Open-market sale: 3,500 Class A shares sold at $87.54 (Code S), generating ≈ $0.31 million in gross proceeds.

Post-transaction, the CFO directly holds 521,595 Class A shares and 70,450 derivative securities. The net reduction of 1,500 shares represents under 0.3 % of his direct equity position, signalling only a marginal change in insider ownership.

Insights

Securities Analyst

TL;DR: Small sale; ownership largely unchanged—minimal signal.

The CFO’s combination of option exercise and subsequent sale is routine portfolio management. Net disposition of 1,500 shares is immaterial versus a remaining stake exceeding 521k shares. The $87.54 sale price is well above the $7.99 exercise cost, but the proceeds represent a fraction of overall insider holdings. There is no indication of broad strategic intent or financial distress. Market impact is expected to be neutral.

Corporate Governance Expert

TL;DR: Rule 10b5-1 plan mitigates governance concerns.

The sale was executed under a pre-arranged Rule 10b5-1 plan adopted 01/15/2025, aligning with best-practice governance standards and reducing the risk of information-based trading allegations. Continued sizable ownership aligns management’s incentives with shareholders. No red flags emerge from this filing.

Filed Pursuant to Rule 424(b)(5)

Registration No. 333-273098

PROSPECTUS SUPPLEMENT

Supplement No. 2 to Prospectus Supplement dated May 3, 2024

$15,000,000

Class A Common Stock

This supplement no. 2 dated July 11, 2025 supplements, modifies and supersedes, only to the extent indicated herein, certain information contained in our prospectus supplement dated May 3, 2024 (the “initial prospectus supplement”) and supplement no. 1 thereto dated September 6, 2024 (“supplement no. 1”), as a part of our registration statement on Form S-3 (File No. 333-273098) (the “Registration Statement”), which we refer to as the initial prospectus supplement, relating to the offer and sale, from time to time, of shares of our Class A common stock, par value $0.001 per share (the “Common Stock”) to or through A.G.P./Alliance Global Partners (“A.G.P.”) and The Benchmark Company, LLC (“Benchmark,” and collectively with A.G.P., the “Agents”) acting as our sales agent, in accordance with the terms of a sales agreement we entered into as of May 3, 2024 (the “Sales Agreement”) with the Agents. This supplement should be read in conjunction with, is not complete without, and may not be delivered or utilized except in connection with, the initial prospectus supplement, including all supplements thereto and documents incorporated by reference therein. If there is any inconsistency between the information in the initial prospectus supplement and this supplement, you should rely on the information in this supplement. Any information that is modified or superseded in the initial prospectus supplement shall not be deemed to constitute a part of the initial prospectus supplement, except as modified or superseded by this supplement.

The sales agreement with the Agents provides that we may issue and sell shares of our Common Stock registered on the Registration Statement from time to time to or through the Agents subject to offering limitations, as applicable, under General Instruction I.B.6. of Form S-3. As of the filing of this prospectus supplement, such offering limitations were not applicable.

As of July 7, 2025, the aggregate market value of our outstanding Common Stock held by non-affiliates, or our public float, was approximately $97,050,138, which amount is based on 15,116,844 outstanding shares of Common Stock held by non-affiliates and a per share price of $6.42, which was the last reported sale price of our Common Stock on the Nasdaq Capital Market on July 7, 2025. Accordingly, under the terms of the sales agreement, we may offer and sell through the initial prospectus supplement, as amended and supplemented by supplement no. 1 and this supplement no. 2, shares of Common Stock having an aggregate offering price of up to $15,000,000 from time to time to or through the Agents. This supplement no. 2 is being filed to update this position, previously reported in supplement no. 1, after the filing of our Annual Report on Form 10-K on June 30, 2025. Through July 11, 2025, we have not sold any shares of Common Stock in accordance with the Sales Agreement under the initial prospectus supplement.

The shares of our Common Stock are listed for trading on The Nasdaq Capital Market (“Nasdaq”) under the symbol “CNVS.” On July 10, 2025, the last reported sale price of the Common Stock on Nasdaq was $6.82 per share.

Investing in our securities involves significant risks. See “Risk Factors” in the initial prospectus supplement, and under similar headings in other documents filed and incorporated by reference herein and therein for a discussion of factors that you should consider before buying shares of the Common Stock.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

A.G.P. The Benchmark Company

The date of this supplement is July 11, 2025.

FAQ

How many Rubrik (RBRK) shares did the CFO sell?

3,500 Class A shares were sold on 07/09/2025 at $87.54 each.

Did the Rubrik CFO exercise any stock options?

Yes, 2,000 options were exercised at a $7.99 strike price, converting into Class A shares.

What is the CFO’s remaining Rubrik shareholding after the transactions?

He directly owns 521,595 Class A shares plus 70,450 derivative securities.

Was the sale made under a Rule 10b5-1 trading plan?

Yes, the filing states the sale occurred under a Rule 10b5-1 plan adopted 01/15/2025.

Is the insider transaction likely to impact RBRK stock materially?

Given the small net sale (≈1,500 shares) relative to total outstanding shares, the market impact is expected to be minimal.